A novel 4′‐brominated derivative of fisetin induces cell cycle arrest and apoptosis and inhibits EGFR / ERK1/2/STAT3 pathways in non‐small‐cell lung cancer without any adverse effects in mice
- 24 November 2022
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 36 (12) , e22654
Abstract
The therapeutic toxicity and resistance to currently available treatment options are major clinical challenges for the management of lung cancer. As a novel strategy, we synthesized analogues of a known flavonol, fisetin, which has shown anti‐tumorigenic potential against cancer in cell culture with no adverse effects in animal models. We studied the synthetic analogues of fisetin for their anti‐cancer potential against lung cancer cells, toxicity in mice and efficacy in a xenograft model. Brominated fisetin analogues were screened for their effects on the viability of A549 and H1299 lung cancer cells, and three analogues ( 3a , 3b , 3c ), showed improved activity compared to fisetin. These analogues were more effective in restricting lung cancer cell proliferation, inducing G 2 M phase cell cycle arrest and apoptosis. The fisetin analogues also downregulated EGFR/ERK1/2/STAT3 pathways. Fisetin analogue‐induced apoptosis was accompanied by a higher Bax to Bcl‐2 expression ratio. Based on the in vitro studies, the most effective fisetin analogue 3b was evaluated for in vivo toxicity, wherein it did not show any hepatotoxicity or adverse health effects in mice. Furthermore, analogue 3b showed greater antitumor efficacy ( p < .001) as compared to its parent compound fisetin in a human lung cancer cell xenograft study in athymic mice. Together, our data suggest that the novel fisetin analogue 3b is more effective in restricting lung cancer cell growth, both in vitro as well as in vivo, without any apparent toxicity, supporting its further development as a novel anti‐lung cancer agent.Keywords
Funding Information
- Department of Science and Technology, Ministry of Science and Technology, India
- South African Agency for Science and Technology Advancement
- University Grants Commission
This publication has 44 references indexed in Scilit:
- Dietary flavonoid fisetin: A novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer managementBiochemical Pharmacology, 2012
- Fisetin, a Dietary Flavonoid, Induces Cell Cycle Arrest and Apoptosis through Activation of p53 and Inhibition of NF‐Kappa B Pathways in Bladder Cancer CellsBasic & Clinical Pharmacology & Toxicology, 2010
- Flavonoids Intake and Risk of Lung Cancer: A Meta-analysisJapanese Journal of Clinical Oncology, 2009
- Dietary flavonoid intake and lung cancer—A population‐based case‐control studyCancer, 2008
- Fisetin, a novel dietary flavonoid, causes apoptosis and cell cycle arrest in human prostate cancer LNCaP cellsCarcinogenesis, 2008
- Methoxylated flavones, a superior cancer chemopreventive flavonoid subclass?Seminars in Cancer Biology, 2007
- Phenylbenzopyrones structure-activity studies identify betuletol derivatives as potential antitumoral agentsEuropean Journal of Pharmacology, 2006
- Effects of Flavonoids on Cell Proliferation and Caspase Activation in a Human Colonic Cell Line HT29: An SAR StudyJournal of Medicinal Chemistry, 2005
- Structure−Activity Requirements for Flavone Cytotoxicity and Binding to TubulinJournal of Medicinal Chemistry, 1998
- Effects of Calmodulin Antagonists on Radiation-induced Lipid Peroxidation in MicrosomesInternational Journal of Radiation Biology, 1990